img

Global Community-acquired Bacterial Pneumonia Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Community-acquired Bacterial Pneumonia Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application

Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.
Community-acquired Bacterial Pneumonia report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Community-acquired Bacterial Pneumonia market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Community-acquired Bacterial Pneumonia industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Community-acquired Bacterial Pneumonia key companies include Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics, Allergan plc, Bayer AG, Lupin Pharmaceuticals, Mylan N.V., Sanofi S.A. and Pfizer Inc., etc. Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics are top 3 players and held % share in total in 2022.
Community-acquired Bacterial Pneumonia can be divided into Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline and Oxazolidinone, etc. Pleuromutilin Antibiotic is the mainstream product in the market, accounting for % share globally in 2022.
Community-acquired Bacterial Pneumonia is widely used in various fields, such as Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, etc. Hospital Pharmacies provides greatest supports to the Community-acquired Bacterial Pneumonia industry development. In 2022, global % share of Community-acquired Bacterial Pneumonia went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Community-acquired Bacterial Pneumonia market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG
Segment by Type
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others

Segment by Application


Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Community-acquired Bacterial Pneumonia market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Community-acquired Bacterial Pneumonia introduction, etc. Community-acquired Bacterial Pneumonia Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Community-acquired Bacterial Pneumonia market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Market Overview of Community-acquired Bacterial Pneumonia
1.1 Community-acquired Bacterial Pneumonia Market Overview
1.1.1 Community-acquired Bacterial Pneumonia Product Scope
1.1.2 Community-acquired Bacterial Pneumonia Market Status and Outlook
1.2 Global Community-acquired Bacterial Pneumonia Market Size Overview by Region 2024 VS 2022 VS 2034
1.3 Global Community-acquired Bacterial Pneumonia Market Size by Region (2024-2034)
1.4 Global Community-acquired Bacterial Pneumonia Historic Market Size by Region (2024-2024)
1.5 Global Community-acquired Bacterial Pneumonia Market Size Forecast by Region (2024-2034)
1.6 Key Regions, Community-acquired Bacterial Pneumonia Market Size (2024-2034)
1.6.1 North America Community-acquired Bacterial Pneumonia Market Size (2024-2034)
1.6.2 Europe Community-acquired Bacterial Pneumonia Market Size (2024-2034)
1.6.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size (2024-2034)
1.6.4 Latin America Community-acquired Bacterial Pneumonia Market Size (2024-2034)
1.6.5 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size (2024-2034)
2 Community-acquired Bacterial Pneumonia Market by Type
2.1 Introduction
2.1.1 Pleuromutilin Antibiotic
2.1.2 Cephalosporin
2.1.3 Glycylcycline
2.1.4 Oxazolidinone
2.1.5 Ketolide
2.1.6 Others
2.2 Global Community-acquired Bacterial Pneumonia Market Size by Type: 2024 VS 2022 VS 2034
2.2.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Type (2024-2024)
2.2.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2024-2034)
2.3 Key Regions Market Size by Type
2.3.1 North America Community-acquired Bacterial Pneumonia Revenue Breakdown by Type (2024-2034)
2.3.2 Europe Community-acquired Bacterial Pneumonia Revenue Breakdown by Type (2024-2034)
2.3.3 Asia-Pacific Community-acquired Bacterial Pneumonia Revenue Breakdown by Type (2024-2034)
2.3.4 Latin America Community-acquired Bacterial Pneumonia Revenue Breakdown by Type (2024-2034)
2.3.5 Middle East and Africa Community-acquired Bacterial Pneumonia Revenue Breakdown by Type (2024-2034)
3 Community-acquired Bacterial Pneumonia Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Community-acquired Bacterial Pneumonia Market Size by Application: 2024 VS 2022 VS 2034
3.2.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Application (2024-2024)
3.2.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Application (2024-2034)
3.3 Key Regions Market Size by Application
3.3.1 North America Community-acquired Bacterial Pneumonia Revenue Breakdown by Application (2024-2034)
3.3.2 Europe Community-acquired Bacterial Pneumonia Revenue Breakdown by Application (2024-2034)
3.3.3 Asia-Pacific Community-acquired Bacterial Pneumonia Revenue Breakdown by Application (2024-2034)
3.3.4 Latin America Community-acquired Bacterial Pneumonia Revenue Breakdown by Application (2024-2034)
3.3.5 Middle East and Africa Community-acquired Bacterial Pneumonia Revenue Breakdown by Application (2024-2034)
4 Community-acquired Bacterial Pneumonia Competition Analysis by Players
4.1 Global Community-acquired Bacterial Pneumonia Market Size by Players (2024-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Community-acquired Bacterial Pneumonia as of 2022)
4.3 Date of Key Players Enter into Community-acquired Bacterial Pneumonia Market
4.4 Global Top Players Community-acquired Bacterial Pneumonia Headquarters and Area Served
4.5 Key Players Community-acquired Bacterial Pneumonia Product Solution and Service
4.6 Competitive Status
4.6.1 Community-acquired Bacterial Pneumonia Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Nabriva Therapeutics
5.1.1 Nabriva Therapeutics Profile
5.1.2 Nabriva Therapeutics Main Business
5.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.1.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.1.5 Nabriva Therapeutics Recent Developments
5.2 Paratek Pharmaceuticals
5.2.1 Paratek Pharmaceuticals Profile
5.2.2 Paratek Pharmaceuticals Main Business
5.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.2.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.2.5 Paratek Pharmaceuticals Recent Developments
5.3 Melinta Therapeutics
5.3.1 Melinta Therapeutics Profile
5.3.2 Melinta Therapeutics Main Business
5.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.3.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.3.5 Allergan plc Recent Developments
5.4 Allergan plc
5.4.1 Allergan plc Profile
5.4.2 Allergan plc Main Business
5.4.3 Allergan plc Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.4.4 Allergan plc Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.4.5 Allergan plc Recent Developments
5.5 Bayer AG
5.5.1 Bayer AG Profile
5.5.2 Bayer AG Main Business
5.5.3 Bayer AG Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.5.4 Bayer AG Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.5.5 Bayer AG Recent Developments
5.6 Lupin Pharmaceuticals
5.6.1 Lupin Pharmaceuticals Profile
5.6.2 Lupin Pharmaceuticals Main Business
5.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.6.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.6.5 Lupin Pharmaceuticals Recent Developments
5.7 Mylan N.V.
5.7.1 Mylan N.V. Profile
5.7.2 Mylan N.V. Main Business
5.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.7.4 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.7.5 Mylan N.V. Recent Developments
5.8 Sanofi S.A.
5.8.1 Sanofi S.A. Profile
5.8.2 Sanofi S.A. Main Business
5.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.8.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.8.5 Sanofi S.A. Recent Developments
5.9 Pfizer Inc.
5.9.1 Pfizer Inc. Profile
5.9.2 Pfizer Inc. Main Business
5.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.9.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.9.5 Pfizer Inc. Recent Developments
5.10 Dainippon Sumitomo Pharma
5.10.1 Dainippon Sumitomo Pharma Profile
5.10.2 Dainippon Sumitomo Pharma Main Business
5.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.10.5 Dainippon Sumitomo Pharma Recent Developments
5.11 Takeda Pharmaceutical Company Limited
5.11.1 Takeda Pharmaceutical Company Limited Profile
5.11.2 Takeda Pharmaceutical Company Limited Main Business
5.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.11.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.11.5 Takeda Pharmaceutical Company Limited Recent Developments
5.12 Basilea Pharmaceutica International AG
5.12.1 Basilea Pharmaceutica International AG Profile
5.12.2 Basilea Pharmaceutica International AG Main Business
5.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Products, Services and Solutions
5.12.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue (US$ Million) & (2024-2024)
5.12.5 Basilea Pharmaceutica International AG Recent Developments
6 North America
6.1 North America Community-acquired Bacterial Pneumonia Market Size by Country (2024-2034)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2024-2034)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2024-2034)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2024-2034)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2024-2034)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Community-acquired Bacterial Pneumonia Market Dynamics
11.1 Community-acquired Bacterial Pneumonia Industry Trends
11.2 Community-acquired Bacterial Pneumonia Market Drivers
11.3 Community-acquired Bacterial Pneumonia Market Challenges
11.4 Community-acquired Bacterial Pneumonia Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Community-acquired Bacterial Pneumonia Market Size (US$ Million) Comparison by Region 2024 VS 2022 VS 2034
Table 2. Global Community-acquired Bacterial Pneumonia Market Size by Region (2024-2024) & (US$ Million)
Table 3. Global Community-acquired Bacterial Pneumonia Market Size Share by Region (2024-2024)
Table 4. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 5. Global Community-acquired Bacterial Pneumonia Forecasted Market Size Share by Region (2024-2034)
Table 6. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million) by Type: 2024 VS 2022 VS 2034
Table 7. Global Community-acquired Bacterial Pneumonia Market Size by Type (2024-2024) & (US$ Million)
Table 8. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2024-2024)
Table 9. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 10. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2024-2034)
Table 11. North America Community-acquired Bacterial Pneumonia Revenue by Type (2024-2024) & (US$ Million)
Table 12. North America Community-acquired Bacterial Pneumonia Revenue by Type (2024-2034) & (US$ Million)
Table 13. Europe Community-acquired Bacterial Pneumonia Revenue by Type (2024-2024) & (US$ Million)
Table 14. Europe Community-acquired Bacterial Pneumonia Revenue by Type (2024-2034) & (US$ Million)
Table 15. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Type (2024-2024) & (US$ Million)
Table 16. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Type (2024-2034) & (US$ Million)
Table 17. Latin America Community-acquired Bacterial Pneumonia Revenue by Type (2024-2024) & (US$ Million)
Table 18. Latin America Community-acquired Bacterial Pneumonia Revenue by Type (2024-2034) & (US$ Million)
Table 19. Middle East and Africa Community-acquired Bacterial Pneumonia Revenue by Type (2024-2024) & (US$ Million)
Table 20. Middle East and Africa Community-acquired Bacterial Pneumonia Revenue by Type (2024-2034) & (US$ Million)
Table 21. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million) by Application: 2024 VS 2022 VS 2034
Table 22. Global Community-acquired Bacterial Pneumonia Market Size by Application (2024-2024) & (US$ Million)
Table 23. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2024-2024)
Table 24. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2024-2034)
Table 26. North America Community-acquired Bacterial Pneumonia Revenue by Application (2024-2024) & (US$ Million)
Table 27. North America Community-acquired Bacterial Pneumonia Revenue by Application (2024-2034) & (US$ Million)
Table 28. Europe Community-acquired Bacterial Pneumonia Revenue by Application (2024-2024) & (US$ Million)
Table 29. Europe Community-acquired Bacterial Pneumonia Revenue by Application (2024-2034) & (US$ Million)
Table 30. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Application (2024-2024) & (US$ Million)
Table 31. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Application (2024-2034) & (US$ Million)
Table 32. Latin America Community-acquired Bacterial Pneumonia Revenue by Application (2024-2024) & (US$ Million)
Table 33. Latin America Community-acquired Bacterial Pneumonia Revenue by Application (2024-2034) & (US$ Million)
Table 34. Middle East and Africa Community-acquired Bacterial Pneumonia Revenue by Application (2024-2024) & (US$ Million)
Table 35. Middle East and Africa Community-acquired Bacterial Pneumonia Revenue by Application (2024-2034) & (US$ Million)
Table 36. Global Community-acquired Bacterial Pneumonia Revenue (US$ Million) by Players (2024-2024)
Table 37. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Players (2024-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Community-acquired Bacterial Pneumonia as of 2022)
Table 39. Date of Key Players Enter into Community-acquired Bacterial Pneumonia Market
Table 40. Global Community-acquired Bacterial Pneumonia Key Players Headquarters and Area Served
Table 41. Community-acquired Bacterial Pneumonia Product Solution and Service
Table 42. Global Community-acquired Bacterial Pneumonia Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Nabriva Therapeutics Basic Information List
Table 45. Nabriva Therapeutics Description and Business Overview
Table 46. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 47. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Nabriva Therapeutics (2024-2024)
Table 48. Nabriva Therapeutics Recent Developments
Table 49. Paratek Pharmaceuticals Basic Information List
Table 50. Paratek Pharmaceuticals Description and Business Overview
Table 51. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 52. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Paratek Pharmaceuticals (2024-2024)
Table 53. Paratek Pharmaceuticals Recent Developments
Table 54. Melinta Therapeutics Basic Information List
Table 55. Melinta Therapeutics Description and Business Overview
Table 56. Melinta Therapeutics Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 57. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Melinta Therapeutics (2024-2024)
Table 58. Melinta Therapeutics Recent Developments
Table 59. Allergan plc Basic Information List
Table 60. Allergan plc Description and Business Overview
Table 61. Allergan plc Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 62. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Allergan plc (2024-2024)
Table 63. Allergan plc Recent Developments
Table 64. Bayer AG Basic Information List
Table 65. Bayer AG Description and Business Overview
Table 66. Bayer AG Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 67. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Bayer AG (2024-2024)
Table 68. Bayer AG Recent Developments
Table 69. Lupin Pharmaceuticals Basic Information List
Table 70. Lupin Pharmaceuticals Description and Business Overview
Table 71. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 72. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Lupin Pharmaceuticals (2024-2024)
Table 73. Lupin Pharmaceuticals Recent Developments
Table 74. Mylan N.V. Basic Information List
Table 75. Mylan N.V. Description and Business Overview
Table 76. Mylan N.V. Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 77. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Mylan N.V. (2024-2024)
Table 78. Mylan N.V. Recent Developments
Table 79. Sanofi S.A. Basic Information List
Table 80. Sanofi S.A. Description and Business Overview
Table 81. Sanofi S.A. Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 82. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Sanofi S.A. (2024-2024)
Table 83. Sanofi S.A. Recent Developments
Table 84. Pfizer Inc. Basic Information List
Table 85. Pfizer Inc. Description and Business Overview
Table 86. Pfizer Inc. Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 87. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Pfizer Inc. (2024-2024)
Table 88. Pfizer Inc. Recent Developments
Table 89. Dainippon Sumitomo Pharma Basic Information List
Table 90. Dainippon Sumitomo Pharma Description and Business Overview
Table 91. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 92. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Dainippon Sumitomo Pharma (2024-2024)
Table 93. Dainippon Sumitomo Pharma Recent Developments
Table 94. Takeda Pharmaceutical Company Limited Basic Information List
Table 95. Takeda Pharmaceutical Company Limited Description and Business Overview
Table 96. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 97. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Takeda Pharmaceutical Company Limited (2024-2024)
Table 98. Takeda Pharmaceutical Company Limited Recent Developments
Table 99. Basilea Pharmaceutica International AG Basic Information List
Table 100. Basilea Pharmaceutica International AG Description and Business Overview
Table 101. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Products, Services and Solutions
Table 102. Revenue (US$ Million) in Community-acquired Bacterial Pneumonia Business of Basilea Pharmaceutica International AG (2024-2024)
Table 103. Basilea Pharmaceutica International AG Recent Developments
Table 104. North America Community-acquired Bacterial Pneumonia Market Size by Country (2024-2024) & (US$ Million)
Table 105. North America Community-acquired Bacterial Pneumonia Market Size by Country (2024-2034) & (US$ Million)
Table 106. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2024-2024) & (US$ Million)
Table 107. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2024-2034) & (US$ Million)
Table 108. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 109. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2024-2024) & (US$ Million)
Table 110. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2024-2034) & (US$ Million)
Table 111. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Region (2024-2024)
Table 112. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Region (2024-2034)
Table 113. Latin America Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 114. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2024-2024) & (US$ Million)
Table 115. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2024-2034) & (US$ Million)
Table 116. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 117. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2024-2024) & (US$ Million)
Table 118. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2024-2034) & (US$ Million)
Table 119. Community-acquired Bacterial Pneumonia Market Trends
Table 120. Community-acquired Bacterial Pneumonia Market Drivers
Table 121. Community-acquired Bacterial Pneumonia Market Challenges
Table 122. Community-acquired Bacterial Pneumonia Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Community-acquired Bacterial Pneumonia Market Size Year-over-Year 2024-2034 & (US$ Million)
Figure 2. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million), 2024 VS 2022 VS 2034
Figure 3. Global Community-acquired Bacterial Pneumonia Market Share by Regions: 2022 VS 2034
Figure 4. Global Community-acquired Bacterial Pneumonia Forecasted Market Size Share by Region (2024-2034)
Figure 5. North America Community-acquired Bacterial Pneumonia Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 6. Europe Community-acquired Bacterial Pneumonia Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 7. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 8. Latin America Community-acquired Bacterial Pneumonia Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 9. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 10. Product Picture of Pleuromutilin Antibiotic
Figure 11. Global Pleuromutilin Antibiotic Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 12. Product Picture of Cephalosporin
Figure 13. Global Cephalosporin Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 14. Product Picture of Glycylcycline
Figure 15. Global Glycylcycline Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 16. Product Picture of Oxazolidinone
Figure 17. Global Oxazolidinone Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 18. Product Picture of Ketolide
Figure 19. Global Ketolide Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 20. Product Picture of Others
Figure 21. Global Others Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 22. Global Community-acquired Bacterial Pneumonia Market Size Share by Type: 2022 & 2034
Figure 23. North America Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2024-2034)
Figure 24. Europe Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2024-2034)
Figure 25. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2024-2034)
Figure 26. Latin America Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2024-2034)
Figure 27. Middle East and Africa Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2024-2034)
Figure 28. Hospital Pharmacies Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 29. Retail Pharmacies Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 30. Online Pharmacies Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 31. Global Community-acquired Bacterial Pneumonia Market Size Share by Application: 2022 & 2034
Figure 32. North America Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2024-2034)
Figure 33. Europe Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2024-2034)
Figure 34. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2024-2034)
Figure 35. Latin America Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2024-2034)
Figure 36. Middle East and Africa Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2024-2034)
Figure 37. Community-acquired Bacterial Pneumonia Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 38. Global Top 5 and Top 10 Players Community-acquired Bacterial Pneumonia Market Share in 2022
Figure 39. North America Community-acquired Bacterial Pneumonia Market Share by Country (2024-2034)
Figure 40. United States Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 41. Canada Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 42. Germany Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 43. France Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 44. U.K. Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 45. Italy Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 46. Russia Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 47. Nordic Countries Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 48. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Region (2024-2034)
Figure 49. China Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 50. Japan Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 51. South Korea Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 52. Southeast Asia Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 53. India Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 54. Australia Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 55. Latin America Community-acquired Bacterial Pneumonia Market Share by Country (2024-2034)
Figure 56. Mexico Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 57. Brazil Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 58. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Country (2024-2034)
Figure 59. Turkey Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 60. Saudi Arabia Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 61. UAE Community-acquired Bacterial Pneumonia Market Size (2024-2034) & (US$ Million)
Figure 62. Bottom-up and Top-down Approaches for This Report

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries